Experimental Manipulation of Sleep and Circadian Rhythms and the Role Played on Reward Function in Teens

NCT ID: NCT04792697

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adolescence is a time of heightened reward sensitivity and greater impulsivity. On top of this, many teenagers experience chronic sleep deprivation and misalignment of their circadian rhythms due to biological shifts in their sleep/wake patterns paired with early school start times. Many studies find that this increases the risk for substance use (SU). However, what impact circadian rhythm and sleep disruption either together or independently have on the neuronal circuitry that controls reward and cognition, or if there are interventions that might help to modify these disruptions is unknown. Project 2 (P2) of the CARRS center will test an innovative and mechanistic model of brain circuitry that uses multi-method approaches, takes a developmental perspective, and incorporates key sleep and reward constructs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Substance use (SU) and substance use disorders (SUD) pose devastating health, financial, and societal costs. The incidence of SU and SUDs increases across adolescence, making this sensitive developmental period one of both heightened risk-and heightened opportunity for prevention and intervention. However, to develop effective interventions investigators need to identify novel and modifiable risk factors and mechanisms for SUD. Sleep and circadian rhythm disturbances are such risk factors, and the reward system, with its increasing sensitivity during adolescence, provides a plausible mechanistic substrate. The focus on sleep, circadian rhythms, and reward system function is particularly salient given the extensive, parallel development of these systems during adolescence, and the plausible linkages between sleep and circadian rhythms, reward function, and SUD risk.

Late sleep timing, short sleep duration and circadian misalignment are associated with increased substance use in teenagers and young adults. The central hypothesis of the Center for Adolescent Reward, Rhythms and Sleep (CARRS) is that adolescent development acts on underlying sleep and circadian traits to modify homeostatic sleep drive, circadian phase, and circadian alignment, which in turn impact cortico-limbic functions critical to SU risk (e.g., reward and cognitive control). Investigators further hypothesize that specific manipulations of sleep and circadian rhythms during adolescence will affect reward responsivity and cognitive control in either positive or negative directions. These manipulations will provide experimental support for our model, and proof of concept for novel clinical interventions to reduce the risk of SU and SUDs.

Most previous studies have examined individual components of circadian rhythms, sleep, and reward function in adolescence. Project 2 (P2) of CARRS will test an innovative and mechanistic model of brain circuitry that uses multi-method approaches, takes a developmental perspective, and incorporates key sleep and reward constructs. Most notably, P2 improves upon past observational work by testing an experimental intervention that manipulates sleep and circadian rhythms to directly examine its impact on reward function and cognitive control.

P2 will study 150 adolescents (age 13-15, 50% female) across two key sleep phenotypes: early sleep timing (low risk, n=50) and late sleep timing (high risk, n=100). All participants will complete the observational study: 2 weeks of home sleep monitoring (actigraphy \& sleep diary), followed by an overnight laboratory visit to assess self-report, behavioral, and neuroimaging (fMRI) tasks tapping cognitive control and reward function, as well as circadian phase via salivary melatonin and molecular rhythms via hair follicles. The Late group will continue to the experimental study, each participant randomized to manipulation or attentional control conditions (n=50 each). Investigators will probe whether advancing sleep/circadian timing and extending sleep duration via sleep scheduling and chronotherapeutic approaches (reducing PM light exposure; administering AM bright light) improves sleep, circadian, and neurobehavioral function relevant to SUD risk. Finally, repeated 6-month follow-up assessments of sleep and SU for all participants are included to examine longitudinal associations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delayed Sleep Phase Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

adolescence sleep substance use reward sensitivity and motivation circadian phase and alignment inhibition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study combines Laboratory, Experimental \& Longitudinal protocols with 2 initial groups (Early Sleep Timing \& Late Sleep Timing). Both groups complete an initial laboratory protocol (baseline). The Late Sleep participants are also randomized to one of two arms (Manipulation or Control) in the experimental protocol (intervention). Early Sleep group does not complete the experimental protocol. Finally, all participants receive follow-up assessments through the life of the grant in the Longitudinal protocol.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advance/Extend Manipulation

For \~2 weeks, Manipulation participants will advance bedtime and regularize wake time. The first night of the manipulation will be conducted in the lab under tightly-controlled experimental conditions. Participants will then go home and for the next 12 days and will be instructed to:

* Sleep scheduling-- advance bedtime by 1.5 hours ( + sleep duration)
* Decrease evening blue light exposure via blue blocker goggles (2 hrs before bed)
* Increase morning bright light exposure via bright light goggles (30 min after rise)
* Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph

Group Type EXPERIMENTAL

Increase morning bright light

Intervention Type OTHER

Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising

Decrease evening blue light

Intervention Type OTHER

Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed

Sleep Scheduling

Intervention Type BEHAVIORAL

Participants will advance their bedtime by 1.5 hours and regularize their wake time

Monitor sleep, mood, and substance use

Intervention Type BEHAVIORAL

Participants will complete smartphone-based sleep, mood, and substance use monitoring

Control

Control participants will complete the baseline laboratory study, then maintain their habitual sleep schedules over the next 12 days at home, with no instruction on sleep timing or light exposure. Control participants will complete smartphone-and text-based assessments and wear an actigraphy watch to monitor their sleep, behavior and sleep habits thereby controlling for effort.

Group Type ACTIVE_COMPARATOR

Monitor sleep, mood, and substance use

Intervention Type BEHAVIORAL

Participants will complete smartphone-based sleep, mood, and substance use monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Increase morning bright light

Participants will wear Re-Timer bright glasses for 30 minutes each morning upon rising

Intervention Type OTHER

Decrease evening blue light

Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed

Intervention Type OTHER

Sleep Scheduling

Participants will advance their bedtime by 1.5 hours and regularize their wake time

Intervention Type BEHAVIORAL

Monitor sleep, mood, and substance use

Participants will complete smartphone-based sleep, mood, and substance use monitoring

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Typically enrolled in a traditional high-school with synchronous learning (in-person or online synchronous learning, but not cyber- or home-schooling) \[school closures during the COVID-19 pandemic are an exception to this\]
* Physically and psychiatrically healthy
* Provision of written informed consent and assent
* Additional inclusion criterion for Experimental protocol: Meets operational definition of late sleep timing (\>10:50PM habitual bedtime)

Exclusion Criteria

* History of alcohol, cannabis, or illicit drug use in the past month, or greater than monthly use in the past year
* Significant or unstable acute or chronic medical conditions
* Frequent headaches or migraines
* History of seizures
* Current serious psychiatric disorder (e.g., depressive disorder, bipolar disorder, eating disorder, psychotic disorder diagnosis, alcohol use disorder or substance use disorder) that would interfere with completion of study procedures
* Current syndromal sleep disorders other than insomnia and delayed sleep phase disorder
* MRI contraindications (i.e., absence of metal in the body, claustrophobia)
* Medications that increase sensitivity to blue light/photosensitizing medications, including psychiatric neuroleptic drugs, psoralen drugs, antiarrhythmic drugs, etc.
* Changes to psychotropic medication regimen in the 2 weeks prior to enrollment, and/or major changes to medications during the study protocol
* If participants have an average bedtime that is later than 3:00AM or an average wake time later than 11:00AM they may be excluded from the study
* Participants should be EXCLUDED for other sleep disorders that require ongoing treatment
* Participants should be EXCLUDED for other sleep disorders that cause significant distress or impairment, per DSM 5 criteria in the Sleep SCID.
Minimum Eligible Age

13 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Brant Hasler

Associate Professor of Psychiatry, Psychology and Clinical and Translational Science

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brant Hasler, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Western Psychiatric Hospital

Pittsburgh, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ronette G Blake, MS

Role: CONTACT

Phone: (412) 246-6443

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ronette G Blake, MS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1P50DA046346-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY20030271

Identifier Type: -

Identifier Source: org_study_id